Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy

Blas, Leandro; Shiota, Masaki; Takamatsu, Dai; Kinoshita, Fumio; Mutoh, T.; Lee, Ken; Monji, Keisuke; Kashiwagi, Eiji; Inokuchi, Junichi; Eto, Masatoshi

doi:10.1007/s00345-022-04245-3

Cited by 2 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On comparing their model with the United States-based Cancer of the Prostate Risk Assessment post-Surgical score using the same validation cohort, the authors showed a higher c-index (0.89 vs. 0.78, P = 0.01) and a positive net benefit at 3 and 5 years postoperatively in the decision curve analyses. 53 …”

Section: Discussionmentioning

confidence: 99%

Prostate cancer nomograms and their application in Asian men: a review

Panaiyadiyan

Kumar

2024

Prostate International

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prostate cancer nomograms and their application in Asian men: a review

Panaiyadiyan

Kumar

2024

Prostate International

View full text Add to dashboard Cite

“…After RP, 15%–30% of men present biochemical recurrence (BCR), 3 with most cases occurring during the first years 4,5 . However, BCR could appear long after the surgery 6 …”

Section: Introductionmentioning

confidence: 99%

“…4,5 However, BCR could appear long after the surgery. 6 BCR is defined as a prostate-specific antigen (PSA) >0.2 ng/mL. 7 An early diagnosis of BCR with early treatment is crucial for better cancer control.…”

Section: Introductionmentioning

confidence: 99%

Validation of schedules for optimal prostate‐specific antigen monitoring after radical prostatectomy

Blas,

Shiota,

Tanegashima

et al. 2023

Int J of Urology

Self Cite

View full text Add to dashboard Cite

BackgroundEarly detection of biochemical recurrence (BCR) after radical prostatectomy (RP) is crucial for early treatment and improving survival outcomes. The optimal prostate‐specific antigen (PSA) monitoring remains unclear, and several models have been proposed. We aimed to externally validate four models for optimal PSA monitoring after RP and propose modifications to improve them.MethodsWe reviewed the clinicopathological data of 896 patients who underwent robot‐assisted RP between 2009 and 2022. We examined all PSA values and estimated the PSA value for four monitoring schedules at each time point in the virtual follow‐up. We defined the ideal PSA for BCR detection between 0.2 and 0.4 ng/mL.ResultsDuring the median follow‐up of 21.4 months, 128 (14.3%) patients presented BCR. The original and modified Keio models, National Cancer Center Hospital model, and American Urological Association/American Society for Radiation Oncology model detected BCR in 14 (10.9%), three (2.3%), 12 (9.4%), and 11 (8.6%) patients with PSA >0.4 ng/mL. Most patients experienced BCR detected with PSA >0.4 ng/mL during the first year postoperative. The modification of interval within 6 months postoperative avoided BCR detection with PSA >0.4 ng/mL within the first year postoperative in 8/9 (88.9%), 1/2 (50.0%), 5/6 (83.3%), and 4/4 (100%) for the original and modified Keio models, National Cancer Center Hospital model, and American Urological Association/American Society for Radiation Oncology model, respectively.ConclusionWe validated four models for PSA monitoring after RP to detect BCR and suggested modifications to avoid detections out of the desired range of PSA. These modifications could help to establish an optimal PSA monitoring schedule after RP.

show abstract

Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy

Cited by 2 publications

References 28 publications

Prostate cancer nomograms and their application in Asian men: a review

Prostate cancer nomograms and their application in Asian men: a review

Validation of schedules for optimal prostate‐specific antigen monitoring after radical prostatectomy

Contact Info

Product

Resources

About